The safety and tolerability of cariprazine in long-term treatment of schizophrenia: A post hoc pooled analysis

BMC Psychiatry

Volumn 17, Issue 1, 2017, Pages

  Nasrallah, Henry A ^a   Earley, Willie ^b   Cutler, Andrew J ^c   Wang, Yao ^b   Lu, Kaifeng ^b   Laszlovszky, István ^d   Németh, György ^d   Durgam, Suresh ^b  

^a SAINT LOUIS UNIVERSITY   (United States)

^b Allergan plc   (United States)

^c Meridien Research   (United States)

^d GEDEON RICHTER LTD   (Hungary)

Author keywords

Atypical antipsychotic; Cariprazine; Long term safety; Open label; Post hoc analysis; Schizophrenia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARIPRAZINE; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROLACTIN; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ADULT; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; BLURRED VISION; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; POST HOC ANALYSIS; PROLACTIN BLOOD LEVEL; PSYCHOSIS; PULSE RATE; RESTLESSNESS; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 85028065748     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-017-1459-z     Document Type: Article

References (41)

1. Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66(2):183-94. quiz 47, 273-4
2. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. Schizophrenia patient outcomes research T. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94-103.
3. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-62.
4. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7(6):268-74.
5. Luft B, Taylor D. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother. 2006;7(13):1739-48.
6. Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry. 2008;69(Suppl 1):18-31.
7. Higashi K, Medic G, Littlewood KJ, Diez T, Granstrom O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200-18.
8. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67(Suppl 5):3-8.
9. Kiss B, Horvath A, Nemethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328-40.
10. Gyertyan I, Kiss B, Saghy K, Laszy J, Szabo G, Szabados T, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925-35.
11. Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology. 2016;233(19-20):3503-12.
12. Caravaggio F, Blumberger D, Nakajima S, Mulsant B, Graff-Guerrerero A. Occupancy of dopamine D3 receptors by aripiprazole in treatment resistant late-life depressed patients depends on length of treatment as evidenced by in vivo imaging with [11C]-(+)-PHNO. Am J Geriatr Psychitary. 2014;22:S83-4.
13. Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, et al. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study with [11C]-(+)-PHNO. Arch Gen Psychiatry. 2009;66(6):606-15.
14. Mizrahi R, Agid O, Borlido C, Suridjan I, Rusjan P, Houle S, et al. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr Res. 2011;131(1-3):63-8.
15. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519-26.
16. Reynolds GP. Histamine and antipsychotic drug-induced weight gain. J Psychopharmacol. 2012;26(12):1608-9.
17. Richelson E. New antipsychotic drugs: how do their receptor-binding profiles compare? J Clin Psychiatry. 2010;71(9):1243-4.
18. Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther. 2012;135(2):113-22.
19. Nakamura T, Kubota T, Iwakaji A, Imada M, Kapas M, Morio Y. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther. 2016;10:327-38.
20. Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574-82.
21. Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2-3):450-7.
22. Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367-73.
23. Cutler AJ, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2017:1-12.
24. Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology. 2017;234(2):199-209.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision. Washington, DC: American Psychiatric Association; 2000.
26. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76.
27. Guy W. Clinical Global Impressions. In: Guy W, editor. ECDEU assessment manual for psychopharmacology: publication ADM 76-338. Rockville: National Institute of Mental Health, Psychopharmacology Research Branch; 1976. p. 217-22.
28. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-77.
29. Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV. Sheehan Suicidality tracking scale (Sheehan-STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder. Psychiatry (Edgmont). 2009;6(1):26-31.
30. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-6.
31. Guy W. The abnormal movement scale. ECDEU assessment manual for psychopharmacology, DHEW publication no. 76-338. Rockville: National Institute of Mental Health; 1976. p. 218-22.
32. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-9.
33. Correll CU, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectr. 2016;21(5):393-402.
34. Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr. 2013;18(1):43-54.
35. Sciarretta A, Piazzi G. Long-term safety of ziprasidone in schizophrenic patients: an open trial. Eur Rev Med Pharmacol Sci. 2012;16(15):2113-9.
36. Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. [published online ahead of print July 7, 2017]. Int Clin Psychopharmacol. Available at: http://journals.lww.com/intclinpsychopharm/Abstract/publishahead/Safety_and_tolerability_of_cariprazine_in_patients.99599.aspx.
37. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(Suppl 4):8-13.
38. Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol. 2010;24(7):1019-29.
39. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assuncao-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70(5):627-43.
40. Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry. 2009;22(3):293-9.
41. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.